Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumors Refractory To Standard Therapy Clear all

Conditions: Tumors
Interventions: Clostridium novyi-NT spores; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, gemcitabine hydrochloride, cisplatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Neoplasms
Interventions: IMC-3C5; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Peoria, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: educational intervention, Titrated pain management, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more

Conditions: Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
Interventions: STP705; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Louisville, Kentucky + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bortezomib, carboplatin, etoposide, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Interventions: MSC2156119J; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Solid Tumor
Interventions: CALAA-01; Drug
Lead sponsor: Calando Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • San Antonio, Texas

Conditions: Advanced Cancers, Solid Tumors
Interventions: Pazopanib, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Cancers
Interventions: Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Houston, Texas

Conditions: Solid Tumors Refractory To Standard Therapy, Neoplasms
Interventions: Kanglaite Injection (KLT); Drug
Lead sponsor: KangLaiTe USA; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Solid Tumors, Lymphoma
Interventions: PU-H71; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor Malignancies
Interventions: Clostridium novyi-NT spores; Biological
Lead sponsor: BioMed Valley Discoveries, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: St Louis, Missouri • The Bronx, New York

Conditions: Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions: SON-DP; Drug
Lead sponsor: Qurgen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more

Conditions: Advanced Solid Tumor
Interventions: HS-110 (viagenpumatucel-L), HS-130; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumor
Interventions: PTX-35; Drug
Lead sponsor: Pelican Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Portland, Oregon • Austin, Texas • San Antonio, Texas

Conditions: Cancer, Tumor, Solid, Refractory Cancer
Interventions: TBX-3400; Biological
Lead sponsor: Taiga Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: MEDI-522; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Refractory Solid Tumors
Interventions: p28; Drug
Lead sponsor: Dr. Tapas K. Das Gupta; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Resistant or Refractory Solid Tumors
Interventions: CAL056 mesylate; Drug
Lead sponsor: Calgent Biotechnology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer, Lung Cancer, Melanoma, Ovarian, NSCLC
Interventions: SI-B036; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 4 more

Conditions: Neoplasms
Interventions: IMC-CS4; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Solid Tumors
Interventions: EMD 1204831; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Unresectable Solid Tumors
Interventions: Andes-1537 for Injection; Drug
Lead sponsor: Andes Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Kanglaite Injection Phase I Study

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

PTX-35 in Patients With Advanced Solid Tumors

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors